aBLA Filing Intelligence & Biosimilar Opportunity

Letybo

Letibotulinumtoxina-Wlbg

Dermatologic

IM Injection

Letybo is an injectable neurotoxin used to soften frown lines between the eyebrows by temporarily relaxing the muscles responsible. It works by blocking acetylcholine release at the neuromuscular junction, reducing muscle contractions and smoothing wrinkles.

Approval Date

29-Feb-24

Data Exclusivity Expiry

29-Feb-28

Market Exclusivity Expiry

29-Feb-36

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

2028

2029

2030

2031

2032

Molecule profile

Details & specifications

Molecule

Letibotulinumtoxina-Wlbg

Innovator

HUGEL, INC.

Dosage Form

IM Injection

Strength

50 units per vial and 100 units per vial

Therapeutic Category

Dermatologic

Usage

To temporarily improve the appearance of moderate-to-severe glabellar lines

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets